ONC SEC Filings: 8-K, 10-Q, S-3 & 424B – BeOne Medicines

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

BeOne Medicines Announces Q3 2026 Financial Results and Raises Full-Year Guidance

Nov 5, 2026

8-K

BeOne Medicines Ltd. Files 2026 Interim Report and Discloses R&D Expense Reconciliation

Aug 26, 2026

8-K

BeOne Medicines Announces Second Quarter 2026 Financial Results and Raised Full-Year Guidance

Aug 5, 2026

8-K

BeOne Medicines Ltd. Settles Tax Audit in China

Jun 26, 2026

8-K

BeOne Medicines Ltd. Announces Results of 2026 Annual General Meeting

Jun 11, 2026

8-K

BeOne Medicines’ BEQALZI™ (sonrotoclax) Receives U.S. FDA Accelerated Approval for Relapsed/Refractory Mantle Cell Lymphoma

May 15, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Mar 10, 2025

424B5

115,055,260 Ordinary Shares-

Dec 1, 2021

424B5

115,055,260 Ordinary Shares-

Nov 23, 2021

424B7

Form 424B7 - Prospectus [Rule 424(b)(7)]

Dec 2, 2020

424B7

Form 424B7 - Prospectus [Rule 424(b)(7)]

Dec 1, 2020

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Jul 13, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 11, 2026

S-3ASR

SHARE RESALE REGISTRATION

May 6, 2026

S-3ASR

May 2026 SHELF

May 6, 2026

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

May 27, 2025

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

May 27, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

May 27, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 16, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 7, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 27, 2025

Ownerships

TYPE

HEADLINE

FILED AT

NEWLee Chan Henry (Reporting)

Nov 9, 2026

144

Form 144 - Report of proposed sale of securities

Nov 6, 2026

144

Form 144 - Report of proposed sale of securities

Nov 5, 2026

Wang Xiaodong (Reporting)

Oct 29, 2026

Wang Xiaodong (Reporting)

Oct 15, 2026

Lee Chan Henry (Reporting)

Oct 2, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Jun 18, 2025

CORRESP

Form CORRESP - Correspondence

Jun 10, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 3, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jun 2, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

May 27, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 10, 2025

BeOne Medicines AG ONC · SEC Filings